Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend ...

Halozyme's ENHANZE technology drives strong near-term growth, but its key patent expires in 2027. Click here to find out why ...

However, Waters has announced plans to merge with BD's life science and diagnostics segment in early 2026, which will dilute that interest in that highly regulated end market, going forward. The ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer discussed President Trump’s tariffs and their impact on the ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

The U.S. Food and Drug Administration has approved Bravecto Quantum, a new shot that protects dogs six months or older ...

The Food and Drug Administration has approved a first of its kind, once-yearly shot designed to protect dogs from fleas and ...

A long-acting flea and tick treatment from Merck Animal Health has earned approval for dogs at least six months old from the ...